Cerenome, Inc. (Nasdaq: CNSY), through its subsidiary CNSide Diagnostics, LLC, has signed an in-network provider agreement with Health Care Service Corporation (HCSC), effective August 1, 2026, to cover the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration assay.

HCSC operates Blue Cross and Blue Shield plans in Texas, Illinois, Montana, New Mexico, and Oklahoma, and offers Medicare Advantage plans in 30 states and Washington, D.C., covering approximately 27.3 million commercial and Medicare Advantage lives.

Combined with previously announced agreements, Cerenome said CNSide now has contracted coverage for approximately 153 million commercial and Medicare Advantage covered lives, which the company said exceeds its full-year 2026 coverage objective ahead of schedule.

"With HCSC, CNSide now has contracted access to approximately 153 million commercial and Medicare Advantage covered lives, exceeding our full-year 2026 coverage objective ahead of schedule," said Marc Hedrick, M.D., Cerenome's President and Chief Executive Officer.

The CNSide® assay is designed to support diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. According to the company, the test has been the subject of 12 peer-reviewed publications and a prospective multicenter study called FORESEE. Since 2020, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions.

The test is available exclusively through CNSide Diagnostics, LLC, as a service to health care professionals in the U.S.